Artwork

Content provided by Ronak Mistry and Rouleaux University Medical Center. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ronak Mistry and Rouleaux University Medical Center or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Episode 090: Prostate Cancer Series, Pt. 7- Treatment for Met. Castrate Resistant Prostate Cancer

 
Share
 

Manage episode 397358400 series 3377633
Content provided by Ronak Mistry and Rouleaux University Medical Center. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ronak Mistry and Rouleaux University Medical Center or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

We made it to the end of another series. In our FINAL episode of the prostate cancer series, we turn our attention to metastatic castrate-resistant prostate cancer! We discuss treatment options, the data behind why we do what we do, and more targeted agents.

Content:

- Approach to metastatic castrate-resistant prostate cancer

- Refresher on what it means to be castrate-resistant

- Role of bisphosphate therapy and denosumab

- Treatment options and data surrounding sequencing of agents

- Other options for prostate cancer (radium-223 and lutetium-177-PSMA-617)

- Role of PARP inhibitors in BRCA-mutated disease

** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Google Podcast

  continue reading

117 episodes

Artwork
iconShare
 
Manage episode 397358400 series 3377633
Content provided by Ronak Mistry and Rouleaux University Medical Center. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ronak Mistry and Rouleaux University Medical Center or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

We made it to the end of another series. In our FINAL episode of the prostate cancer series, we turn our attention to metastatic castrate-resistant prostate cancer! We discuss treatment options, the data behind why we do what we do, and more targeted agents.

Content:

- Approach to metastatic castrate-resistant prostate cancer

- Refresher on what it means to be castrate-resistant

- Role of bisphosphate therapy and denosumab

- Treatment options and data surrounding sequencing of agents

- Other options for prostate cancer (radium-223 and lutetium-177-PSMA-617)

- Role of PARP inhibitors in BRCA-mutated disease

** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Google Podcast

  continue reading

117 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide